Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib redifferentiation therapy for radioiodine-refractory RET-rearranged papillary thyroid cancer
ChiCTR2300074017Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pralsetinib in thyroid cancer, papillary thyroid cancer (PTC) and well-differentiated thyroid cancer (WDTC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Overall response rate. Started Aug 2023; status: recruiting.
02
Drugs
pralsetinib
03
Conditions
thyroid cancerpapillary thyroid cancer (PTC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2300074017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074017.